Navigation Links
Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million.

Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent that has demonstrated promising antitumor activity in Phase 1 and Phase 2 clinical trials.

"This important round of financing provides us with funds necessary to continue to advance our pipeline of promising oncology products through clinical development and to achieve a number of corporate and clinical milestones.  This includes the completion of the ongoing JX-594 Phase 2 clinical trials currently underway for patients with liver cancer and colorectal cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We appreciate the support from many of our existing stockholders as well as a number of new important investors who chose to participate in this successful financing."

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Pusan, South Korea.  For more information about Jennerex, please visit

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
2. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
3. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
6. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
9. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
10. Resverlogix Completes Dosing for ASSERT Trial
11. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):